Generic semaglutide arrives as Canadian employer coverage of weight loss drugs reaches 37 percent

More than a third of Canadian employers now pay for GLP-1 drugs used for weight loss as well as diabetes, and generic semaglutide is about to test how long that lasts. A July survey put the share at 37% in 2026, against 17% two years earlier. A new broker report now tells plan sponsors to rewrite their rules before cheaper copies of Ozempic and Wegovy reach the pharmacy shelf in volume. Who saves, and how much, depends on plan design rather than on the approvals alone.

What the employer survey found

The numbers come from the International Foundation of Employee Benefit Plans, which has tracked Canadian GLP-1 coverage since February 2024 and published its 2026 results on July 7. Plans that cover the drugs for both diabetes and weight loss rose from 17% in 2024 to 31% in 2025 and 37% this year. Plans that limit them to diabetes fell over the same period, and 12% of employers now also cover them for other conditions such as sleep apnea and heart disease. Most weight loss coverage, 85% of it, sits inside the ordinary prescription drug benefit. Smaller groups use a dedicated weight management vendor or a separate drug rider. Among employers that still do not cover weight loss, 17% said they are thinking about adding it.

The same survey shows why finance teams watch this line so closely. Among the ten respondents that shared claims data, GLP-1 drugs made up 11.1% of annual drug claims on average in 2026. That is one drug class taking a large slice of a whole benefit. Some employers are also steering costs away from the plan itself: 15% encourage staff to pay for the drugs through a health care spending account, and 2% point employees toward a direct to consumer platform. Those routes shift the bill onto the worker or onto a fixed account balance. The survey does not report what employees pay out of pocket, so it cannot say whether broader employer coverage has made the medicines easier to afford for the typical worker or only easier to claim.

Three generic approvals in three months

Health Canada made Canada the first G7 country to approve a generic version of semaglutide on April 28, 2026. A second approval followed on May 1, when an Apotex product for adults with type 2 diabetes was cleared. On June 29 the regulator approved its third generic, Sevmia, also from Apotex, and the first generic semaglutide cleared for chronic weight management. It is a once weekly injection for people aged 12 and older, used alongside a lower calorie diet and more physical activity, and it is the generic match for Wegovy. At that point six more generic submissions from other companies were still under review, and the agency said further decisions would come in the following weeks and months.

Plans that cover the drugs for both diabetes and weight loss rose from 17% in 2024 to 31% in 2025 and 37% this year.

Health Canada said generics are expected to bring potential savings for patients and the health system, and noted that many generic medicines in Canada cost 45% to 90% less than the brand. That is a general statement about generics, not a price for any semaglutide product. The release gave no launch date, no price and no word on public or private coverage for Sevmia. Approval also does not mean supply. A company still has to make enough pens, ship them and win listings on drug plans and provincial formularies. For readers who want to know how a single pen ends up with several different prices, our guide to list price and net price explains who pays what along the chain.

What plan sponsors are told to do

Lockton Canada, an insurance broker, used its first market update, released in October, to frame the generics as a rare chance to slow drug spending. The report tells employers to check plan design and generic substitution rules so that savings are captured when lower cost versions appear, and to reassess how they cover GLP-1 drugs, especially for weight loss, as prices fall. "Drug-cost inflation isn't necessarily a one-way trend; plan design, generic substitution and formulary management can materially change the trajectory," the report states. Lockton cites the survey figures above as evidence that coverage has grown fast enough to make the choice urgent. The report gives no estimate of savings for a typical plan, and none should be assumed from it.

The report also quotes a more cautious payer. In a February release cited by Lockton, Alberta Blue Cross said GLP-1 therapies and a growing list of other high cost specialty drugs will keep pushing costs up, and that savings from generics and biosimilars will not be enough to cancel that out. Both views can hold at once. A plan that moves members onto a cheaper product may cut its cost per member, while total spending still climbs because more people qualify and stay on treatment. Employers in the United States have faced the same tension, and some large insurers there have used formulary choices to steer members toward one brand. Canadian plan sponsors are being nudged toward similar tools now.

What changes for workers at the counter

For a worker with a drug plan, the practical question is whether the plan will pay for a brand, a generic or both, and on what terms. According to the coverage of the Lockton report, Health Canada has said the effect on any single employer plan will depend on product availability, plan design, formulary decisions and the substitution rules that apply. In plain terms, a plan with mandatory generic substitution could pay only up to the generic price and leave the member to cover the gap if they insist on the brand. A plan without that rule may keep paying for the brand as before. Pharmacists will sit in the middle of those choices, since substitution happens at the dispensing counter and depends on what stock the pharmacy can actually get.

Several things are not yet known. Neither Health Canada nor Lockton has published a Canadian price for generic semaglutide, and there is no public date for when the weight loss generic will be widely stocked. It is also unclear how many employers will expand employer coverage once prices fall, and how many will instead add tighter rules such as prior approval or step therapy. People who pay cash face a separate question that no plan answers, and they should rely only on licensed pharmacies and approved products rather than unregulated copies sold online. Workers who are unsure what their own plan covers can ask their benefits administrator for the drug list and the substitution policy that applies to them.

Conclusion

Coverage of GLP-1 drugs for weight loss has more than doubled among Canadian employers since 2024, and generic semaglutide arrives just as plan sponsors are being told to tighten the rules. The approvals are real, but prices, launch timing and plan listings are still open. Workers should watch for changes to substitution rules and drug lists at their next plan renewal.